A 30-year-old man who has sex with men is seen in a clinic with the plan to start HIV preexposure prophylaxis (PrEP). His last sexual encounter was 6 weeks ago. He prefers taking daily oral medication for HIV PrEP, and the plan is to use daily oral tenofovir alafenamide-emtricitabine. He has never received HIV preexposure prophylaxis or HIV postexposure prophylaxis. He is asymptomatic.
In addition to performing standard screening for sexually transmitted infections, what baseline laboratory studies should be performed prior to starting tenofovir DF-emtricitabine as HIV PrEP?

Figure 1. Recommended Baseline Laboratory Studies in Persons Starting HIV PrEP
*If any of the following: use of oral HIV PrEP or oral postexposure prophylaxis medications in the past 3 months, previously received cabotegravir or lenacapavir-SQ, had high-risk exposure to HIV in prior 4 weeks, or has signs/symptoms that suggest acute HIV infection.
^If the person receiving HIV PrEP is a woman with pregnancy potential
Abbreviations: eCrCL = estimated creatinine clearance; MSM = men who have sex with men; PWID = persons who inject drugs
Siource: Centers for Disease Control and Prevention: US Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 Update: a clinical practice guideline. December 2021:1-108.
Sign In or Register Progress Not Saved!
Since you are not signed in, your progress won't be saved.
Since you are not signed in, your progress won't be saved.
Question Last Updated
July 22nd, 2025
July 22nd, 2025
Steps to Acquire CE for this Question Bank Topic:
1
Answer
Answer all questions
2
Score 80%+
Answer correctly
3
Claim CE
Choose CNE or CME
4
Give Feedback
Complete survey
5